Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INHIBITION OF DEXTROMETHORPHAN METABOLISM BY MOCLOBEMIDE
Autore:
HARTTER S; DINGEMANSE J; BAIER D; ZIEGLER G; HIEMKE C;
Indirizzi:
UNIV MAINZ,DEPT PSYCHIAT,UNTER ZAHLBACHER STR 8 D-55101 MAINZ GERMANY UNIV MAINZ,DEPT PSYCHIAT D-55101 MAINZ GERMANY CLIN PHARMA RES LTD BIRSFELDEN SWITZERLAND HOFFMANN LA ROCHE AG GRENZACH WYHLEN GERMANY INST PSYCHOSOMAT RES STUTTGART GERMANY
Titolo Testata:
Psychopharmacology
fascicolo: 1, volume: 135, anno: 1998,
pagine: 22 - 26
Fonte:
ISI
Lingua:
ENG
Soggetto:
SECONDARY OXIDATIVE-METABOLISM; HUMAN LIVER-MICROSOMES; CYP2D6; PHARMACOKINETICS; DEMETHYLATION; SPARTEINE; RAT;
Keywords:
DEXTROMETHORPHAN; MOCLOBEMIDE; CYP2D6; DRUG INTERACTIONS; POOR METABOLIZER; EXTENSIVE METABOLIZER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
22
Recensione:
Indirizzi per estratti:
Citazione:
S. Hartter et al., "INHIBITION OF DEXTROMETHORPHAN METABOLISM BY MOCLOBEMIDE", Psychopharmacology, 135(1), 1998, pp. 22-26

Abstract

This pilot study was conducted to evaluate the potential of the new antidepressant moclobemide to inhibit the cytochrome enzyme P4502D6 (CYP2D6) using the cough suppressant dextromethorphan as a substrate in four extensive metabolizers (EM) of debrisoquine. The subjects receivedseven oral doses of 20 mg dextromethorphan at 4-h intervals over 2 days (1 and 2) and subsequently moclobemide (300 mg b.i.d.) for 9 days. On days 10 and 11, they received seven doses of 20 mg dextromethorphanin addition to moclobemide. During monotreatment and combined treatment, blood was collected on days 2 and 11, respectively, for determination of dextromethorphan and its demethylated metabolites using automated high-performance liquid chromatography with column switching. Concurrent administration of moclobemide markedly reduced the O-demethylation of dextromethorphan, whereas the N-demethylation of dextrorphan to hydroxymorphinan was not affected. The findings indicate that moclobemide can affect the pharmacokinetics of drugs that are mainly metabolized by CYP2D6.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 09:21:44